CDMO Alcami reports that it has significantly expanded the cold, stability, and custom storage options at its new 65,000 ft2 pharma storage facility in Garner, NC, near Research Triangle Park. Company officials say the facility offers diverse, customizable, scalable, long-term storage conditions for temperature-sensitive vaccines, biopharma therapies, cell banks, tissues, pharmaceutical compounds, raw materials, components, and medical devices.

“Alcami’s new facility is well positioned to fill previously unmet market demand,” notes Laurent Boer, president, Alcami Pharma Storage and Services. “The pipeline of complex medicines, exactly the type of ground-breaking products that life science companies in RTP work on, is only increasing. The biopharmaceutical materials and products in these drugs require specific warehouse conditions that this new facility provides. We offer a comprehensive pharma storage network paired with seamless access to our integrated laboratory and manufacturing services.”

After opening in January with controlled/ambient storage, the facility can now accept shipments for a range of storage conditions, including stability chamber storage, refrigerated storage, freezer, ultra-low freezer, and cryogenic storage (LN2) as well as custom conditions, Boer continues.

In addition, the site now offers a full suite of materials management and support services that facilitate the full product development, storage, and commercialization journey, including onsite aliquoting/sampling in grade C sampling booths, refrigerated transport, labeling, cycle counting/inventory management, custom kitting, and reference standards management, he adds.

The new facility expands Alcami’s GMP storage network to six U.S. locations across the Northeast, Southeast, and West Coast. Alcami’s network covers a range of GMP temperature storage conditions, including all ICH stability conditions, according to Boer.

Previous articleGenetic Disorders Diagnosed More Quickly via Long-Read Sequencing Method
Next articleGEN Chat: Complete Genomics’ Rade Drmanac Talks NGS Then and Now